KiroBlock
Latest Information Update: 15 Sep 2023
At a glance
- Originator Kiromic
- Class Antineoplastics
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Acute myeloid leukaemia; Colorectal cancer; Multiple myeloma; Ovarian cancer
Most Recent Events
- 15 Sep 2023 Discontinued - Preclinical for Acute myeloid leukaemia in USA (unspecified route) before September 2023
- 15 Sep 2023 Discontinued - Preclinical for Colorectal cancer in USA (unspecified route) before September 2023
- 15 Sep 2023 Discontinued - Preclinical for Multiple myeloma in USA (unspecified route) before September 2023